Efficacy of Procox® Oral Suspension for Dogs (0.1% Emodepside and 2% Toltrazuril) against Experimental Nematode (Toxocara cati and Ancylostoma tubaeforme) Infections in Cats

Abstract

Two exploratory studies were performed to determine the optimum therapeutic dose of Procox(®) for the removal of experimental infection with mature adult Toxocara (T.) cati and Ancylostoma (A.) tubaeforme in kittens. Procox(®) is a new oral suspension containing a combination of the nematocidal and coccidiocidal active principles emodepside (0.1 %) and toltrazuril (2 %).In the first study, 18 eight-weeks-old kittens were inoculated with 450 L3 larvae of T. cati. 56 days after infection, the kittens were allocated to three treatment groups and were treated with 0.5 mg emodepside/kg body weight (group 1), 0.25 mg emodepside/kg body weight (group 2) and 0.1 mg emodepside/kg body weight (group 3), respectively. In the second study, 10 eight-weeks-old kittens were inoculated with 350 L3 larvae of A. tubaeforme. Four weeks after infection, the kittens were allocated to two treatment groups and were treated with 0.1 mg emodepside/kg body weight (group 1) or 0.25 mg emodepside/kg body weight (group 2). In both studies, all kittens received a reference treatment with Drontal(®) (230 mg pyrantel embonate and 20 mg praziquantel per tablet) at the recommended dose of one tablet/4 kg body weight 5 days after treatment with Procox(®). Anthelmintic efficacy was calculated by reduction in worm numbers expelled with the faeces following treatment with Procox(®) as compared with faecal worm numbers after reference treatment with Drontal(®), by thus avoiding necropsy of the animals.In the T. cati study, emodepside was at 99.9 %, 100 % and 96.5 % effective at a dosage of 0.5 mg, 0.25 mg and 0.1 mg per kg body weight, respectively. Against A. tubaeforme emodepside was at 95.7 % and 100 % effective at a dosage of 0.1 mg and 0.25 mg per kg body weight. No adverse events were seen during either study.It can be concluded that Procox(®) is efficacious for the control of mature adult T. cati and A. tubaeforme infections in cats at a single-dose rate of 0.25 mg emodepside/kg body weight.

Pet roundworms and hookworms: A continuing need for global worming

“…A multicentre investigation carried out across Europe has also indicated efficacy of 100% and 99.9% against T. canis and Ancylostomatidae based on faecal egg count reduction [143]. This oral suspension for dogs has been also proved to be effective in experimental feline infections by T. cati and A. tubaeforme [144]. …”

“…87.5%) of the owned pets treated with oral tablets containing pyrantel/oxantel/praziquantel has been documented [134] and, analogously, practices across Europe have reported a high acceptance by dogs treated with the oral tablets containing emodepside [141]. The oral suspension containing emodepside and toltrazuril has an acceptance rated as good and medium in 90% and 9% respectively, in dogs treated in the multi-center study mentioned above [143] and high palatability when administered in cats [144]. Flavoured chewable tablets containing milbemycin oxime presented also high acceptance by treated animals, going from 64% to 94.8% directly from the owners’ hand [141,169].…”

Морфологічні Та Біохімічні Дослідження Крові Інвазованих Собак Та Котів Під Час Застосування Препарату «Брованол-С»

“…Боротьба з гельмінтними інвазіями свійських собак та котів є нагальною проблемою та вимагає застосування антигельмінтних препаратів, перелік яких постійно поповнюється. Виробники протипаразитарних препаратів у всьому світі розробляють комбіновані антигельмінтні препарати, які мають ефективний лікувальний результат, що підтверджують дослідження науковців [1][2][3][4][5]. Проте зміни клініко-гематологічних показників інвазованих тварин під час застосування лікувальних засобів потребують докладного вивчення, про що неодноразово ідеться в наукових публікаціях [6][7][8][9][10].…”